These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Overcoming COVID-19 in West African countries: is herd immunity an option? Ilesanmi OS; Akande A; Afolabi AA Pan Afr Med J; 2020; 35(Suppl 2):103. PubMed ID: 33282058 [TBL] [Abstract][Full Text] [Related]
25. Lessons learned from the SARS-CoV-2 pandemic; from nucleic acid nanomedicines, to clinical trials, herd immunity, and the vaccination divide. Hussain H; Ganesh A; Milane L; Amiji M Expert Opin Drug Deliv; 2023 Apr; 20(4):489-506. PubMed ID: 36890642 [TBL] [Abstract][Full Text] [Related]
26. Looking beyond COVID-19 as a pandemic. Lau YL Hong Kong Med J; 2021 Apr; 27(2):88-89. PubMed ID: 33843608 [No Abstract] [Full Text] [Related]
27. Individuals cannot rely on COVID-19 herd immunity: Durable immunity to viral disease is limited to viruses with obligate viremic spread. Yewdell JW PLoS Pathog; 2021 Apr; 17(4):e1009509. PubMed ID: 33901246 [No Abstract] [Full Text] [Related]
28. Network models to evaluate vaccine strategies towards herd immunity in COVID-19. Tetteh JNA; Nguyen VK; Hernandez-Vargas EA J Theor Biol; 2021 Dec; 531():110894. PubMed ID: 34508758 [TBL] [Abstract][Full Text] [Related]
29. The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a Recurrent Seasonal Infection? Murray CJL; Piot P JAMA; 2021 Apr; 325(13):1249-1250. PubMed ID: 33656519 [No Abstract] [Full Text] [Related]
30. How to Understand Herd Immunity in the Context of COVID-19. Dong M; He F; Deng Y Viral Immunol; 2021 Apr; 34(3):174-181. PubMed ID: 33351708 [TBL] [Abstract][Full Text] [Related]
31. Influence of heterogeneous age-group contact patterns on critical vaccination rates for herd immunity to SARS-CoV-2. Saldaña J; Scoglio C Sci Rep; 2022 Feb; 12(1):2640. PubMed ID: 35173229 [TBL] [Abstract][Full Text] [Related]
32. Could COVID-19 be contained in poor populations by herd immunity rather than by strategies designed for affluent societies or potential vaccine(s)? Ruppel A; Halim MI; Kikon R; Mohamed NS; Saebipour MR Glob Health Action; 2021 Jan; 14(1):1863129. PubMed ID: 33397199 [No Abstract] [Full Text] [Related]
33. Are COVID vaccination programmes working? Scientists seek first clues. Mallapaty S Nature; 2021 Jan; 589(7843):504-505. PubMed ID: 33483685 [No Abstract] [Full Text] [Related]
34. Can COVID-19 vaccines stop the pandemic? Lau CS Hong Kong Med J; 2021 Apr; 27(2):84-85. PubMed ID: 33879622 [No Abstract] [Full Text] [Related]
35. Challenges in Engendering Herd Immunity to SARS-CoV-2 Infection: Possibly Impossible But Plausibile. Mukherjee S; Ray SK Infect Disord Drug Targets; 2022; 22(4):e170122200309. PubMed ID: 35040409 [TBL] [Abstract][Full Text] [Related]
36. Herd immunity to endemic diseases: Historical concepts and implications for public health policy. Robertson D; Heriot G; Jamrozik E J Eval Clin Pract; 2024 Jun; 30(4):625-631. PubMed ID: 38562003 [TBL] [Abstract][Full Text] [Related]
38. An Appraisal of the Current Scenario in Vaccine Research for COVID-19. Chong WC; Chellappan DK; Shukla SD; Peterson GM; Patel RP; Jha NK; Eri RD; Dua K; Tambuwala MM; Shastri MD Viruses; 2021 Jul; 13(7):. PubMed ID: 34372603 [TBL] [Abstract][Full Text] [Related]
39. What Is Herd Immunity? Desai AN; Majumder MS JAMA; 2020 Nov; 324(20):2113. PubMed ID: 33074287 [No Abstract] [Full Text] [Related]
40. Herd immunity: challenges and the way forward in Korea. Oh J; Kim S; Ryu B; Shin M; Kim BI Epidemiol Health; 2021; 43():e2021054. PubMed ID: 34412446 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]